Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 37-39, 2007.
Artigo
em Inglês
| WPRIM
| ID: wpr-212923
ABSTRACT
A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib as a second line treatment, which resulted in a partial response with response duration of 6 months. After progression of the disease, the patient received erlotinib, which resulted in partial response again with response duration of 11.5 months. This observation suggests that treatment with erlotinib may be effective in patients who develop progressive disease after a primary treatment with gefitinib following an initial response.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Proteínas Tirosina Quinases
/
Adenocarcinoma
/
Cloridrato de Erlotinib
/
Pulmão
/
Neoplasias Pulmonares
Limite:
Idoso
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Cancer Research and Treatment
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS